HNB
CRSP icon

Huntington National Bank’s CRISPR Therapeutics CRSP Stock Holding History

Huntington National Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09K Buy
+75
New +$3.95K ﹤0.01% 2295
2025
Q2 		– Sell
-17
Closed -$579 – 4169
2025
Q1 		$579 Hold
17
– – ﹤0.01% 2442
2024
Q4 		$669 Sell
17
-287
-94% -$13.6K ﹤0.01% 2455
2024
Q3 		$14.3K Hold
304
– – ﹤0.01% 1626
2024
Q2 		$16.4K Hold
304
– – ﹤0.01% 1524
2024
Q1 		$20.7K Hold
304
– – ﹤0.01% 1448
2023
Q4 		$19K Buy
304
+34
+13% +$1.88K ﹤0.01% 1430
2023
Q3 		$12.3K Hold
270
– – ﹤0.01% 1499
2023
Q2 		$15.2K Hold
270
– – ﹤0.01% 1447
2023
Q1 		$12.2K Sell
270
-15
-5% -$729 ﹤0.01% 1472
2022
Q4 		$11.6K Sell
285
-5
-2% -$265 ﹤0.01% 1448
2022
Q3 		$19K Hold
290
– – ﹤0.01% 1305
2022
Q2 		$17K Hold
290
– – ﹤0.01% 1388
2022
Q1 		$18K Hold
290
– – ﹤0.01% 1403
2021
Q4 		$22K Hold
290
– – ﹤0.01% 1343
2021
Q3 		$32K Sell
290
-160
-36% -$20.1K ﹤0.01% 1095
2021
Q2 		$73K Buy
450
+160
+55% +$19.5K ﹤0.01% 827
2021
Q1 		$35K Hold
290
– – ﹤0.01% 942
2020
Q4 		$44K Buy
290
+90
+45% +$10.6K ﹤0.01% 858
2020
Q3 		$17K Hold
200
– – ﹤0.01% 1100
2020
Q2 		$15K Buy
+200
New +$11.7K ﹤0.01% 1117

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Huntington National Bank's CRSP Position: Q2 2026 in Review

Huntington National Bank opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 75 shares worth $4.09K. The stake represents ﹤0.01% of the portfolio and ranks #2295 among its holdings. This is a return to the name: Huntington National Bank previously reported a position in CRSP as recently as Q1 2025.

Huntington National Bank first reported a position in CRSP in Q2 2020 and has held it in 21 quarters since. The position peaked at $73K in Q2 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Huntington National Bank held 75 shares of CRISPR Therapeutics worth $4.09K as of Q2 2026.
  • CRISPR Therapeutics was a new Huntington National Bank position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Huntington National Bank's portfolio in Q2 2026, its #2295 holding.
  • Huntington National Bank first reported a position in CRISPR Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Huntington National Bank's CRISPR Therapeutics position peaked at $73K in Q2 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Huntington National Bank's 13F filing for Q2 2026, filed 13 Aug 2026.